Bayer Withdraws Trasylol

Brooks Schuelke

Contributor

0 CommentsPrint ArticleSubscribe

Under pressure from the Food and Drug Administration, Bayer announced today that it is suspending its global sales of Trasylol. The drug, primarily used to help with bleeding during heart surgeries, has been linked to higher instances of death, serious kidney damage, and stroke. Bayer has been under attack for problems relating to Trasylol for more than a year after Bayer failed to provide the FDA with data related to the drug's risks that Bayer obtained from an analysis of 67,000 Trasylol patients.

For more information on this subject, please refer to the section on Drugs, Medical Devices, and Implants.